ONWARD Information

ONWARD Medical is a neurotechnology company pioneering therapies to restore movement, function, and independence in people living with spinal cord injuries and other movement disabilities. Our purpose-designed technology platforms are designed to deliver targeted, programmed spinal cord stimulation: · The external ARC-EX® System is the first FDA-cleared device for both clinic and at-home use indicated to improve hand strength and sensation after spinal cord injury. ARC-EX is supported by 10+ peer-reviewed publications. It was named one of TIME magazine’s Best Inventions and recognized among Fast Company’s World Changing Ideas for its potential to transform lives. · The investigational ARC-IM® System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is designed to address several unmet needs, including blood pressure instability after spinal cord injury. Empower BP is the first global pivotal study to evaluate the safety and effectiveness of the investigational ARC-IM in addressing blood pressure instability in people living with SCI. · The investigational ARC-BCI® System is the world’s most advanced purpose-built platform pairing a brain-computer interface with an implantable spinal cord stimulation system and artificial intelligence to restore thought-driven movement after paralysis. We are dedicated to addressing the most pressing needs of people living with SCI and other movement disabilities. We collaborate closely with rehabilitation clinics, caregivers, and people living with SCI to accelerate innovation and access to care. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD), and its US ADRs can be traded on OTCQX (ticker: ONWRY).